Navigation Links
Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
Date:1/28/2009

EAST BRUNSWICK, N.J., Jan. 28 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that its biologics license application (BLA) for pegloticase for treatment-failure gout will be reviewed by the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) on March 5, 2009 as required for a drug of a new therapeutic class.

Savient submitted its BLA to the FDA on October 31, 2008 seeking approval to market pegloticase in the United States. On December 29, 2008, the FDA accepted the BLA filing for review and granted priority review. A priority review is an FDA designation that is assigned to products that if approved, would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious or life-threatening disease. Under priority review, the target date for an FDA decision on the pegloticase BLA is April 30, 2009.

Savient's filing includes data from both the six-month placebo-controlled Phase 3 pivotal trials, as well as data from the open label extension (OLE) study. The two replicate six-month Phase 3 clinical trials for pegloticase were performed under the auspices of a Special Protocol Assessment (SPA) (2006). Pegloticase was granted orphan drug designation by the FDA in 2001.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The Company's product development candidate, pegloticase for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; and t
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... LUTHERVILLE, Md. , Aug. 20, 2014 /PRNewswire/ ... today lauded the latest results achieved by the ... known as the National Precursor Log Exchange (NPLEx), ... enforcement officials track down methamphetamine offenders and make ... in Missouri blocked the ...
(Date:8/20/2014)... SOUTH PLAINFIELD, N.J. , Aug. 20, 2014 PTC ... it will participate at two upcoming investor conferences: ... Four Seasons Hotel in Boston on ... Annual Biotech Conference at The Mandarin Oriental Boston on Thursday, ... will present a company update at the Bank of America ...
(Date:8/20/2014)... 2014 Reportlinker.com announces that a new ... The Impact of Healthcare Reform (PPACA) ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html The "Patient Protection ... legislation that affects virtually every aspect of health ... to take effect now. IVD manufacturers who have ...
Breaking Medicine Technology:Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2PTC Therapeutics to Participate at Upcoming Investor Conferences 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6
(Date:8/20/2014)... (PRWEB) August 20, 2014 The Board ... Perkins Eastman is pleased to announce the ... services in China and the surrounding region. ... Richard Sprow AIA has relocated to the ... career in healthcare planning and design and to better ...
(Date:8/20/2014)... persistent and deadliest infectious diseases in the world, killing ... who study tuberculosis have long debated its origins. New ... Africa to seals and sea lions that brought the ... people there before Europeans landed on the continent. , ... Source of New World Human Tuberculosis," was published in ...
(Date:8/20/2014)... Sockeye salmon that sprint to spawning grounds through fast-moving ... University of British Columbia scientists. , When salmon encounter ... downstream of dams they must move upstream using ... to sprinting for humans. , "Days after sockeye passed ... dying only a short distance from their spawning grounds," ...
(Date:8/20/2014)... 2014 As concerns regarding the health ... ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgery continue to ... from New York are urging the U.S. Food & ... devices. In a letter dated August 19th, Sens. Kirsten ... agency to seriously consider the testimony given during the ...
(Date:8/20/2014)... Research from Columbia University Medical Center shows that ... growth and that blocking nerve signals using surgery or ... disease. The study was conducted by the laboratory of ... MD, PhD, in Norway and is published in today,s ... have long observed that human and mouse cancers contain ...
Breaking Medicine News(10 mins):Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... A visionary leader, Dr.,Maria Cristina Escobar Fritzsche ... contributions to the prevention and control of ... Pan American Sanitary Conference,proceedings today. The Abraham ... bestowed upon creative leaders whose commitment to,public ...
... LMAT ), a provider of peripheral vascular devices ... to launch a,direct sales force in Italy in January ... Italy through an,exclusive distribution agreement with Serom Medical Technologies ... rights on,January 25, 2008 in exchange for the payment ...
... - A cadre of private and public entities in ... National Adopting Changes to Improve Outcomes Now (ACTION) Campaign ... Campaign goals are to increase access to addiction treatment ... in treatment. , The campaign, launched during National ...
... APFC ), today announced that Chairman and Chief,Executive ... Operating,officer, Dr. Joseph Carleone, and Vice President and Chief ... the CIBC World Market,2nd Annual Industrials Conference, October 2-3, ... is available on the Company,s web site. About ...
... combined treatment with rapamycin and Gleevec might reverse the ... disease, according to the results of a new study ... of Hepatology, a journal published by John Wiley & ... Study of Liver Diseases (AASLD). The article is also ...
... This strategy beat out either therapy alone, researchers found ... combination of cognitive behavior therapy plus antidepressant drugs is ... thoughts and behavior in depressed teens, new research shows. ... October issue of the journal Archives of General ...
Cached Medicine News:Health News:Inter-American Leadership Award Bestowed Upon Chilean Chronic Disease Expert 2Health News:LeMaitre Vascular to Start Italian Sales Force 2Health News:LeMaitre Vascular to Start Italian Sales Force 3Health News:Leaders in addiction treatment announce national 'ACTION' campaign 2Health News:Combination therapy reverses effects of portal hypertension in rats 2Health News:Drug Plus Psychotherapy Best Treatment for Depressed Teens 2
Long handle occluders are approximately 9 inches long....
Long handle occluders are approximately 9 inches long....
Basic external reading model....
Manual Lensmeter....
Medicine Products: